Cellebrite Slides as Guidance Cut and ARR Miss Overshadow Q2 Growth

Cellebrite DI Ltd. (CLBT) is down 31.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp selloff appears tied mainly to a weaker outlook after the company said second-quarter ARR came in below expectations and lowered its full-year 2026 ARR and revenue guidance. Investors also may be reacting to signs of slower deal timing and softer expansion activity, while a same-day CEO transition likely added another layer of uncertainty.

Details:

Cellebrite reported second-quarter 2026 ARR of $507.8 million and revenue of $131.1 million, both up year over year, but ARR landed below the company’s prior second-quarter target of $510 million to $513 million.

The company cut its full-year 2026 ARR outlook to $550 million to $560 million from $567 million to $573 million, and reduced its revenue outlook to $555 million to $561 million from $565 million to $571 million.

Management pointed to longer sales cycles and less expansion from Inseyets conversions than anticipated, suggesting the demand environment and conversion pace were not as strong as investors expected.

Cellebrite also announced that Shiven Ramji became CEO effective immediately, succeeding Thomas E. Hogan, and leadership changes announced alongside lowered guidance can sometimes intensify market volatility.

Sources:

Cellebrite Investor Relations, SEC, Cellebrite Quarterly Results

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CLBT Insider Trading Activity

$CLBT insiders have traded $CLBT stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $CLBT stock by insiders over the last 6 months:

THOMAS E. HOGAN (Chief Executive Officer) sold 103,188 shares for an estimated $1,625,892
DAVID BARTER (Chief Financial Officer) sold 41,734 shares for an estimated $683,419
MARCUS JEWELL (Global Chief Revenue Officer) has made 0 purchases and 3 sales selling 13,452 shares for an estimated $173,243.
DAVID NICHOLAS GEE (Chief Marketing Officer) has made 0 purchases and 4 sales selling 6,131 shares for an estimated $81,138.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive CLBT Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CLBT Hedge Fund Activity

We have seen 130 institutional investors add shares of $CLBT stock to their portfolio, and 108 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS removed 2,405,172 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,143,270
COOPER CREEK PARTNERS MANAGEMENT LLC removed 2,395,973 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,016,507
BLACKROCK, INC. added 2,344,395 shares (+70.2%) to their portfolio in Q2 2026, for an estimated $34,228,167
PHOENIX FINANCIAL LTD. added 2,000,000 shares (+47.8%) to their portfolio in Q2 2026, for an estimated $29,200,000
MEITAV INVESTMENT HOUSE LTD removed 1,954,846 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $28,540,751
CAPITAL WORLD INVESTORS added 1,897,225 shares (+880.4%) to their portfolio in Q2 2026, for an estimated $27,699,485
WEISS ASSET MANAGEMENT LP added 1,846,851 shares (+3485.3%) to their portfolio in Q1 2026, for an estimated $25,449,606

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CLBT Price Targets

Multiple analysts have issued price targets for $CLBT recently. We have seen 2 analysts offer price targets for $CLBT in the last 6 months, with a median target of $17.5.

Here are some recent targets:

Rudy Kessinger from DA Davidson set a target price of $20.0 on 05/27/2026
Mike Cikos from Needham set a target price of $15.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.